Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
23 Nov 2023
23 Nov 2023
Historique:
received:
14
07
2023
accepted:
06
11
2023
revised:
24
10
2023
medline:
24
11
2023
pubmed:
24
11
2023
entrez:
23
11
2023
Statut:
aheadofprint
Résumé
FOLFOXIRI plus bevacizumab has demonstrated benefits for metastatic colorectal cancer (mCRC) patients. However, challenges arise in its clinical implementation due to expected side effects and a lack of stratification criteria. The AIO "CHARTA" trial randomised mCRC patients into clinical Group 1 (potentially resectable), 2 (unresectable/risk of rapid progression), or 3 (asymptomatic). They received FOLFOX/bevacizumab +/- irinotecan. The primary endpoint was the 9-month progression-free survival rate (PFSR@9). Secondary endpoints included efficacy in stratified groups, QoL, PFS, OS, ORR, secondary resection rate, and toxicity. The addition of irinotecan to FOLFOX/bevacizumab increased PFSR@9 from 56 to 67%, meeting the primary endpoint. The objective response rate was 61% vs. 69% (P = 0.21) and median PFS was 10.3 vs. 12 months (HR 0.83; P = 0.17). The PFS was (11.4 vs. 12.9 months; HR 0.83; P = 0.46) in potentially resectable patients, with a secondary resection rate of 37% vs. 51%. Moreover, Group 3 (asymptomatic) patients had a PFS of 11.1 vs. 16.1 months (HR 0.6; P = 0.14). The addition of irinotecan did not diminish QoL. The CHARTA trial, along with other studies, confirms the efficacy and tolerability of FOLFOXIRI/bevacizumab as a first-line treatment for mCRC. Importantly, clinical stratification may lead to its implementation. The trial was registered as NCT01321957.
Sections du résumé
BACKGROUND
BACKGROUND
FOLFOXIRI plus bevacizumab has demonstrated benefits for metastatic colorectal cancer (mCRC) patients. However, challenges arise in its clinical implementation due to expected side effects and a lack of stratification criteria.
METHODS
METHODS
The AIO "CHARTA" trial randomised mCRC patients into clinical Group 1 (potentially resectable), 2 (unresectable/risk of rapid progression), or 3 (asymptomatic). They received FOLFOX/bevacizumab +/- irinotecan. The primary endpoint was the 9-month progression-free survival rate (PFSR@9). Secondary endpoints included efficacy in stratified groups, QoL, PFS, OS, ORR, secondary resection rate, and toxicity.
RESULTS
RESULTS
The addition of irinotecan to FOLFOX/bevacizumab increased PFSR@9 from 56 to 67%, meeting the primary endpoint. The objective response rate was 61% vs. 69% (P = 0.21) and median PFS was 10.3 vs. 12 months (HR 0.83; P = 0.17). The PFS was (11.4 vs. 12.9 months; HR 0.83; P = 0.46) in potentially resectable patients, with a secondary resection rate of 37% vs. 51%. Moreover, Group 3 (asymptomatic) patients had a PFS of 11.1 vs. 16.1 months (HR 0.6; P = 0.14). The addition of irinotecan did not diminish QoL.
CONCLUSION
CONCLUSIONS
The CHARTA trial, along with other studies, confirms the efficacy and tolerability of FOLFOXIRI/bevacizumab as a first-line treatment for mCRC. Importantly, clinical stratification may lead to its implementation.
TRIAL REGISTRATION
BACKGROUND
The trial was registered as NCT01321957.
Identifiants
pubmed: 37996507
doi: 10.1038/s41416-023-02496-4
pii: 10.1038/s41416-023-02496-4
doi:
Banques de données
ClinicalTrials.gov
['NCT01321957']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, Kramar A, et al. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist. 2011;16:1557–64. https://doi.org/10.1634/theoncologist.2011-0141
doi: 10.1634/theoncologist.2011-0141
pubmed: 22016477
pmcid: 3233290
Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol J Am Soc Clin Oncol. 2007;25:1670–6. https://doi.org/10.1200/JCO.2006.09.0928
doi: 10.1200/JCO.2006.09.0928
Folprecht G, Hamann S, Schütte K, Trarbach T, Stoehlmacher-Williams J, Ehninger G. Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer. BMC Cancer. 2014;14:521 https://doi.org/10.1186/1471-2407-14-521
doi: 10.1186/1471-2407-14-521
pubmed: 25038824
pmcid: 4223588
Fornaro L, Lonardi S, Masi G, Loupakis F, Bergamo F, Salvatore L, et al. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol J Eur Soc Med Oncol. 2013;24:2062–7. https://doi.org/10.1093/annonc/mdt165
doi: 10.1093/annonc/mdt165
Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer. 2010;103:1542–7. https://doi.org/10.1038/sj.bjc.6605940
doi: 10.1038/sj.bjc.6605940
pubmed: 20959822
pmcid: 2990583
Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol J Am Soc Clin Oncol. 2009;27:672–80. https://doi.org/10.1200/JCO.2008.19.8135
doi: 10.1200/JCO.2008.19.8135
Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol. 2010;11:845–52. https://doi.org/10.1016/S1470-2045(10)70175-3
doi: 10.1016/S1470-2045(10)70175-3
pubmed: 20702138
Bajetta E, Celio L, Ferrario E, Di Bartolomeo M, Denaro A, Dotti K, et al. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Ann Oncol J Eur Soc Med Oncol. 2007;18:1810–6. https://doi.org/10.1093/annonc/mdm347
doi: 10.1093/annonc/mdm347
Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006;94:798–805. https://doi.org/10.1038/sj.bjc.6603011
doi: 10.1038/sj.bjc.6603011
pubmed: 16508637
pmcid: 2361370
Stein A, Atanackovic D, Hildebrandt B, Stübs P, Brugger W, Hapke G, et al. Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer. Br J Cancer. 2015;113:872–7. https://doi.org/10.1038/bjc.2015.299
doi: 10.1038/bjc.2015.299
pubmed: 26335608
pmcid: 4578090
Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJM, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. New Engl J Med. 2009;360:563–72. https://doi.org/10.1056/NEJMoa0808268
doi: 10.1056/NEJMoa0808268
pubmed: 19196673
Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Guimbaud R, et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharm. 2008;62:195–201. https://doi.org/10.1007/s00280-007-0588-3
doi: 10.1007/s00280-007-0588-3
Zarate R, Rodríguez J, Bandres E, Patiño-Garcia A, Ponz-Sarvise M, Viudez A, et al. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br J Cancer. 2010;102:987–94. https://doi.org/10.1038/sj.bjc.6605595
doi: 10.1038/sj.bjc.6605595
pubmed: 20216541
pmcid: 2844042
Bendell JC, Zakari A, Peyton JD, Boccia R, Moskowitz M, Gian V, et al. A phase II study of FOLFOXIRI plus panitumumab followed by evaluation for resection in patients with metastatic KRAS wild-type colorectal cancer with liver metastases only. Oncologist. 2016b;21:279–80. https://doi.org/10.1634/theoncologist.2015-0439
doi: 10.1634/theoncologist.2015-0439
pubmed: 26911408
pmcid: 4786359
Bruera G, Santomaggio A, Cannita K, Baldi PL, Tudini M, De Galitiis F, et al. Poker” association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer. 2010;10:567 https://doi.org/10.1186/1471-2407-10-567
doi: 10.1186/1471-2407-10-567
pubmed: 20958992
pmcid: 2972284
Gruenberger T, Bridgewater J, Chau I, García Alfonso P, Rivoire M, Mudan S, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol J Eur Soc Med Oncol. 2015;26:702–8. https://doi.org/10.1093/annonc/mdu580
doi: 10.1093/annonc/mdu580
Hurwitz HI, Tan BR, Reeves JA, Xiong H, Somer B, Lenz H-J, et al. Phase II randomized trial of sequential or concurrent FOLFOXIRI-bevacizumab versus FOLFOX-bevacizumab for metastatic colorectal cancer (STEAM). Oncologist. 2019;24:921–32. https://doi.org/10.1634/theoncologist.2018-0344
doi: 10.1634/theoncologist.2018-0344
pubmed: 30552157
Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. New Engl J Med. 2014;371:1609–18. https://doi.org/10.1056/NEJMoa1403108
doi: 10.1056/NEJMoa1403108
pubmed: 25337750
Stein A, Glockzin G, Wienke A, Arnold D, Edelmann T, Hildebrandt B, et al. Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC Cancer. 2012;12:356 https://doi.org/10.1186/1471-2407-12-356
doi: 10.1186/1471-2407-12-356
pubmed: 22897915
pmcid: 3503684
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020a;21:497–507. https://doi.org/10.1016/S1470-2045(19)30862-9
doi: 10.1016/S1470-2045(19)30862-9
pubmed: 32164906
Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer: a personalized approach to clinical decision making. Ann Oncol J Eur Soc Med Oncol. 2012;23:2479–516. https://doi.org/10.1093/annonc/mds236
doi: 10.1093/annonc/mds236
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol J Am Soc Clin Oncol. 2008;26:2013–9. https://doi.org/10.1200/JCO.2007.14.9930
doi: 10.1200/JCO.2007.14.9930
Sastre J, Vieitez JM, Gomez-España MA, Gil Calle S, Salud Salvia A, Suárez BG, et al. Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs). J Clin Oncol. 2019;37:3507. https://doi.org/10.1200/JCO.2019.37.15_suppl.3507
doi: 10.1200/JCO.2019.37.15_suppl.3507
Bendell JC, Tan BR, Reeves JA, Xiong H, Somer BG, Lenz H-J, et al. Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2016a;34:492. https://doi.org/10.1200/jco.2016.34.4_suppl.492
doi: 10.1200/jco.2016.34.4_suppl.492
Cremolini C, Antoniotti C, Stein A, Bendell J, Gruenberger T, Rossini D, et al. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol. 2020, https://doi.org/10.1200/JCO.20.01225 .
Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306–15. https://doi.org/10.1016/S1470-2045(15)00122-9
doi: 10.1016/S1470-2045(15)00122-9
pubmed: 26338525
Vassilev Z, Fan X, Ostojic H, Xu J, Barzi A. Use of FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (mCRC): An age-stratified analysis. J Clin Oncol. 2023;41:64 https://doi.org/10.1200/JCO.2023.41.4_suppl.64
doi: 10.1200/JCO.2023.41.4_suppl.64